We are looking for a dispersion system for dry powders. Our lead compound Remimazolam (short acting benzodiazepine for use in procedural sedation and general anesthesia, as iv infusion) is currently in late stage of clinical development and we have recently became very interested in developing an intranasal application. We would therefore be very interested in discussing with you possibility of using your expertise in intranasal device and formulation development. Please let us know if this would be of interest for you? We could establish a CDA as a next step or have an initial introductory call. Looking forward to your response Best Regards Aasim Amin

Service Category(s)
Key Service(s)
Life Science Sector
Supporting Documents